Management of Autoimmune and Cholestatic Liver Disorders

Clinics in Liver Disease

Volumn 13, Issue 2, 2009, Pages 295-316

  Krok, Karen L ^a   Munoz, Santiago J ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Autoimmune hepatitis; Biliary cirrhosis; Cholestasis; Liver transplantation; Overlap syndrome; Sclerosing cholangitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDRALAZINE; INTERFERON; ISONIAZID; MERCAPTOPURINE; METHOTREXATE; METHYLDOPA; MINOCYCLINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NALMEFENE; NALTREXONE; NITRATE; NITROFURANTOIN; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PREDNISONE; RIFAMPICIN; SERTRALINE; TACROLIMUS; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ADJUVANT THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CHRONIC PAIN; CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG MEGADOSE; ENDOSCOPIC SURGERY; ESOPHAGUS SPASM; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPOTHYROIDISM; INTRAHEPATIC CHOLESTASIS; KIDNEY TUBULE DISORDER; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; METABOLIC BONE DISEASE; MONOTHERAPY; NEPHROTOXICITY; PLASMAPHERESIS; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRURITUS; RAYNAUD PHENOMENON; REVIEW; SCLEROSING CHOLANGITIS; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SURVIVAL RATE; THROMBOCYTOPENIA; TOXIC HEPATITIS; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VITAMIN DEFICIENCY; VOMITING; WITHDRAWAL SYNDROME;

ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CARCINOMA, HEPATOCELLULAR; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; CHRONIC DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; PREDNISONE; URSODEOXYCHOLIC ACID;

EID: 65149087546     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2009.02.011     Document Type: Review

References (132)

1. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31 (1999) 929
2. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 354 (2006) 54
3. Krawitt E.L. Clinical features and management of autoimmune hepatitis. World J Gastroenterol 14 (2008) 3301
4. Lee W.M., and Seremba E. Etiologies of acute liver failure. Curr Opin Crit Care 14 (2008) 198
5. Kanzler S., Weidemann C., Gerken G., et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 31 (1999) 635
6. Czaja A.J. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 96 (2001) 1224
7. Czaja A.J., Carpenter H.A., and Manns M.P. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 105 (1993) 1522
8. Invernizzi P., and Mackay I.R. Autoimmune liver diseases. World J Gastroenterol 14 (2008) 3290
9. Choi G., and Peters M.G. The challenge of diagnosing autoimmune hepatitis: less is more. Hepatology 48 (2008) 10
10. Luxon B.A. Diagnosis and treatment of autoimmune hepatitis. Gastroenterol Clin North Am 37 (2008) 461
11. Czaja A.J., Menon K.V., and Carpenter H.A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35 (2002) 890
12. Mackay I.R. Historical reflections on autoimmune hepatitis. World J Gastroenterol 14 (2008) 3292
13. Soloway R.D., and Hewlett A.T. The medical treatment for autoimmune hepatitis through corticosteroid to new immunosuppressive agents: a concise review. Ann Hepatol 6 (2007) 204
14. Larsen F.S. Treatment of patients with severe autoimmune hepatitis. Minerva Gastroenterol Dietol 54 (2008) 57
15. Ford T.J., and Dillon J.F. Minocycline hepatitis. Eur J Gastroenterol Hepatol 20 (2008) 796
16. Bianchi F.B., Muratori P., Granito A., et al. Hepatitis C and autoreactivity. Dig Liver Dis 39 Suppl 1 (2007) S22
17. Ferri C., Antonelli A., Mascia M.T., et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 39 Suppl 1 (2007) S13
18. Fried M.W., Draguesku J.O., Shindo M., et al. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 38 (1993) 631
19. Strassburg C.P., Vogel A., and Manns M.P. Autoimmunity and hepatitis C. Autoimmun Rev 2 (2003) 322
20. Hennes E.M., Oo Y.H., Schramm C., et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. Am J Gastroenterol 103 (2008) 3063-3070
21. Inductivo-Yu I., Adams A., Gish R.G., et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 5 (2007) 799
22. Ayata G., Gordon F.D., Lewis W.D., et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 32 (2000) 185
23. Narumi S., Hakamada K., Sasaki M., et al. Liver transplantation for autoimmune hepatitis: rejection and recurrence. Transplant Proc 31 (1955) 1999
24. Gonzalez-Koch A., Czaja A.J., Carpenter H.A., et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 7 (2001) 302
25. Heffron T.G., Smallwood G.A., Oakley B., et al. Autoimmune hepatitis following liver transplantation: relationship to recurrent disease and steroid weaning. Transplant Proc 34 (2002) 3311
26. Reich D.J., Fiel I., Guarrera J.V., et al. Liver transplantation for autoimmune hepatitis. Hepatology 32 (2000) 693
27. Salcedo M., Vaquero J., Banares R., et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 35 (2002) 349
28. Tillmann H.L., Jackel E., and Manns M.P. Liver transplantation in autoimmune liver disease-selection of patients. Hepatogastroenterology 46 (1999) 3053
29. Balasubramaniam K., Grambsch P.M., Wiesner R.H., et al. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 98 (1990) 1567
30. Mahl T.C., Shockcor W., and Boyer J.L. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 20 (1994) 707
31. Myszor M., and James O.F. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease?. Q J Med 75 (1990) 377
32. Prince M.I., Chetwynd A., Craig W.L., et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53 (2004) 865
33. Van de Water J., Cooper A., Surh C.D., et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 320 (1989) 1377
34. Kaplan M.M., and Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 353 (2005) 1261
35. Coppel R.L., McNeilage L.J., Surh C.D., et al. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A 85 (1988) 7317
36. Poupon R., Chretien Y., Poupon R.E., et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1 (1987) 834
37. Combes B., Luketic V.A., Peters M.G., et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 99 (2004) 264
38. Heathcote E.J., Cauch-Dudek K., Walker V., et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19 (1994) 1149
39. Lindor K.D., Dickson E.R., Baldus W.P., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106 (1994) 1284
40. Pares A., Caballeria L., Rodes J., et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 32 (2000) 561
41. Poupon R.E., Balkau B., Eschwege E., et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 324 (1991) 1548
42. Gong Y., Huang Z., Christensen E., et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 102 (2007) 1799
43. Goulis J., Leandro G., and Burroughs A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354 (1999) 1053
44. Shi J., Wu C., Lin Y., et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 (2006) 1529
45. Poupon R.E., Lindor K.D., Pares A., et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39 (2003) 12
46. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128 (2005) 297
47. Lindor K.D., Jorgensen R.A., Therneau T.M., et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 72 (1997) 1137
48. Christensen E., Neuberger J., Crowe J., et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89 (1985) 1084
49. Gong Y., Christensen E., and Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev 3 (2007) CD006000
50. Mitchison H.C., Palmer J.M., Bassendine M.F., et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15 (1992) 336
51. Lombard M., Portmann B., Neuberger J., et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104 (1993) 519
52. Minuk G.Y., Bohme C.E., Burgess E., et al. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Gastroenterology 95 (1988) 1356
53. Wiesner R.H., Ludwig J., Lindor K.D., et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 322 (1990) 1419
54. Gong Y., Christensen E., and Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database Syst Rev 3 (2007) CD005526
55. Bodenheimer Jr. H., Schaffner F., and Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 95 (1988) 124
56. Kaplan M.M., Alling D.W., Zimmerman H.J., et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315 (1986) 1448
57. Warnes T.W., Smith A., Lee F.I., et al. A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol 5 (1987) 1
58. Zifroni A., and Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 14 (1991) 990
59. Gong Y., and Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am J Gastroenterol 100 (2005) 1876
60. Vuoristo M., Farkkila M., Karvonen A.L., et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 108 (1995) 1470
61. Babatin M.A., Sanai F.M., and Swain M.G. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment Pharmacol Ther 24 (2006) 813
62. Bach N., Bodian C., Bodenheimer H., et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 187
63. Bonis P.A., and Kaplan M. Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol. Gastroenterology 117 (1999) 395
64. Buscher H.P., Zietzschmann Y., and Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol 18 (1993) 9
65. Hendrickse M.T., Rigney E., Giaffer M.H., et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117 (1999) 400
66. Kaplan M.M., DeLellis R.A., and Wolfe H.J. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 126 (1997) 682
67. Kaplan M.M., and Knox T.A. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 101 (1991) 1332
68. Kaplan M.M., Schmid C., Provenzale D., et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 117 (1999) 1173
69. Lindor K.D., Dickson E.R., Jorgensen R.A., et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology 22 (1995) 1158
70. Combes B., Emerson S.S., Flye N.L., et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 42 (2005) 1184
71. Kaplan M.M., Cheng S., Price L.L., et al. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 39 (2004) 915
72. Johnson P.J., Krasner N., Portmann B., et al. Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis. Gut 19 (1978) 1022
73. Deutsch M., Papatheodoridis G.V., Tzakou A., et al. Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 20 (2008) 5
74. Turissini S.B., and Kaplan M.M. Hepatocellular carcinoma in primary biliary cirrhosis. Am J Gastroenterol 92 (1997) 676
75. Jones D.E., Metcalf J.V., Collier J.D., et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26 (1997) 1138
76. Shibuya A., Tanaka K., Miyakawa H., et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35 (2002) 1172
77. Suzuki A., Lymp J., Donlinger J., et al. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 5 (2007) 259
78. Silveira M.G., Suzuki A., and Lindor K.D. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 48 (2008) 1149
79. Lee J., Belanger A., Doucette J.T., et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 5 (2007) 1313
80. Dickson E.R., Grambsch P.M., Fleming T.R., et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 10 (1989) 1
81. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 33 (2001) 22
82. Neuberger J., Gunson B., Hubscher S., et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 10 (2004) 488
83. Datta D.V., and Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J 1 (1963) 216
84. Ghent C.N., Bloomer J.R., and Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 73 (1977) 1125
85. Matsuzaki Y., Tanaka N., Osuga T., et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 85 (1990) 15
86. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45 (2007) 666
87. Browning J., Combes B., and Mayo M.J. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 2736
88. Bachs L., Pares A., Elena M., et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102 (1992) 2077
89. Ghent C.N., and Carruthers S.G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94 (1988) 488
90. Thornton J.R., and Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ 297 (1988) 1501
91. Bergasa N.V., Alling D.W., Talbot T.L., et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 123 (1995) 161
92. Wolfhagen F.H., Sternieri E., Hop W.C., et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 113 (1997) 1264
93. Cohen L.B., Ambinder E.P., Wolke A.M., et al. Role of plasmapheresis in primary biliary cirrhosis. Gut 26 (1985) 291
94. Poupon R.E., Poupon R., and Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 330 (1994) 1342
95. Cerio R., Murphy G.M., Sladen G.E., et al. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol 116 (1987) 265
96. Becker M., von Bergmann K., Rotthauwe H.W., et al. Effects of phenobarbital on biliary lipid metabolism in children with chronic intrahepatic cholestasis. Eur J Pediatr 143 (1984) 41
97. Giovannini A., Ballardini G., Amatetti S., et al. Patterns of lacrimal dysfunction in primary biliary cirrhosis. Br J Ophthalmol 69 (1985) 832
98. Mang F.W., Michieletti P., O'Rourke K., et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia 12 (1997) 167
99. Reynolds T.B., Denison E.K., Frankl H.D., et al. Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome. Am J Med 50 (1971) 302
100. Navasa M., Pares A., Bruguera M., et al. Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J Hepatol 5 (1987) 292
101. Thornton J.R., Triger D.R., and Losowsky M.S. Variceal bleeding is associated with reduced risk of severe cholestasis in primary biliary cirrhosis. Q J Med 71 (1989) 467
102. Boyer T.D., Kokenes D.D., Hertzler G., et al. Effect of distal splenorenal shunt on survival of patients with primary biliary cirrhosis. Hepatology 20 (1994) 1482
103. Springer J.E., Cole D.E., Rubin L.A., et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 118 (2000) 145
104. Menon K.V., Angulo P., Weston S., et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35 (2001) 316
105. Hodgson S.F., Dickson E.R., Wahner H.W., et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 103 (1985) 855
106. Janes C.H., Dickson E.R., Okazaki R., et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 95 (1995) 2581
107. Guanabens N., Pares A., Ros I., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 2268
108. Wolfhagen F.H., van Buuren H.R., den Ouden J.W., et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 26 (1997) 325
109. Zein C.O., Jorgensen R.A., Clarke B., et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42 (2005) 762
110. Camisasca M., Crosignani A., Battezzati P.M., et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 20 (1994) 633
111. Matloff D.S., Kaplan M.M., Neer R.M., et al. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 83 (1982) 97
112. Dawson-Hughes B., Heaney R.P., Holick M.F., et al. Estimates of optimal vitamin D status. Osteoporos Int 16 (2005) 713
113. Lanspa S.J., Chan A.T., Bell III J.S., et al. Pathogenesis of steatorrhea in primary biliary cirrhosis. Hepatology 5 (1985) 837
114. Munoz S.J., Heubi J.E., Balistreri W.F., et al. Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology 9 (1989) 525
115. Phillips J.R., Angulo P., Petterson T., et al. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 96 (2001) 2745
116. Elta G.H., Sepersky R.A., Goldberg M.J., et al. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig Dis Sci 28 (1983) 971
117. Charatcharoenwitthaya P., and Lindor K.D. Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 8 (2006) 75
118. Cullen S.N., and Chapman R.W. Review article: current management of primary sclerosing cholangitis. Aliment Pharmacol Ther 21 (2005) 933
119. Mendes F.D., and Lindor K.D. Primary sclerosing cholangitis. Clin Liver Dis 8 (2004) 195
120. Silveira M.G., and Lindor K.D. Primary sclerosing cholangitis. Can J Gastroenterol 22 (2008) 689
121. Tischendorf J.J., Geier A., and Trautwein C. Current diagnosis and management of primary sclerosing cholangitis. Liver Transpl 14 (2008) 735
122. Weismuller T.J., Wedemeyer J., Kubicka S., et al. The challenges in primary sclerosing cholangitis-aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 48 Suppl 1 (2008) S38
123. Harnois D.M., Angulo P., Jorgensen R.A., et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96 (2001) 1558
124. Mitchell S.A., Bansi D.S., Hunt N., et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121 (2001) 900
125. Olsson R., Boberg K.M., de Muckadell O.S., et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129 (2005) 1464
126. Lindor K., Enders F., Schmoll J., et al. Randomized, double-blind, controlled trial of high-dose ursodeoxycholic acid (UDCA) for primary sclerosing cholangitis. Hepatology 48 Suppl 4 (2008) 378A
127. Baluyut A.R., Sherman S., Lehman G.A., et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 53 (2001) 308
128. Mishima S., Omagari K., Ohba K., et al. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology 55 (2008) 221
129. Premoli A., Morello E., Bo S., et al. Diagnostic and therapeutic questions in overlap syndromes of autoimmune hepatitis. Minerva Gastroenterol Dietol 53 (2007) 79
130. Rust C., and Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 14 (2008) 3368
131. Sherlock S. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. Clin Liver Dis 4 (2000) 97
132. van Buuren H.R., van Hoogstraten H.J.E., Terkivatan T., et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 33 (2000) 543